Colon cancer genetic marker

Prevenirea cancerului prin intermediul unor programe de screening Iniţial s-a vrut a fi un marker serologic specific pentru carcinomul colorectal care să pună precoce diagnosticul la pacienţii asimptomatici, dar curând s-a demonstrat că niveluri serice ridicate apar şi în alte cancere, în afecţiuni non- maligne intestinale şi chiar la indivizi normali atunci când îşi schimbă brusc obiceiurile de fumat sau băut.

Valorile ACE ridicate la pacienţii cu cancer colorectal depind şi de prezenţa vaselor sangvine peritumorale, de reactia inflamatorie imună la celulele colon cancer genetic heterogeneity şi de starea celulelor Kupfer hepatice care deţin receptori capabili de-a lega această glicoproteină şi a-i favoriza clearance-ul din colon cancer genetic marker [4].

In prezent, oamenii de colon cancer genetic marker fac eforturi pentru a dezvolta noi tehnici care sa ajute la tintirea celulelor canceroase.

Cellular phenotypic changes characteristic of EMT can be induced by the absence of transition cofactor p involved colon cancer genetic marker cellular regulation. Colon cancer genetic factors of syndecan-1 marker is associated with local tumor stage and metastasis. Colorectal Cancer Gene Screens Modulators of protein kinase resistance was associated with changes in genes involved in EMT including vimentin hyperexpression and genes involved in invasion N-cadherin with a decrease expression of genes involved in epithelial cell adhesion E-cadherin.

Progression in colon cancer is characterized by activating mutations in Ras genes and tumor growth factor action. Vimentin expression associated with EMT initiates molecular program.

The benefits are certain in some cases: life years gained for those with curable disease, avoidance of morbidity, reassurance that the disease is at a very early stage, avoiding expenses of treatment for colon cancer genetic marker cancers and extra years of productivity. But screening tests also have disadvantages, so a balanced decision must be made, with the help of clinical randomized trials.

In this article I will present the current methods for screening accepted for general population and particular screening reserved for persons at high risk.

Although in the first case the benefit is proven, the use of these methods in practice varies largely due to lack of resources and well designed health programs. TGF-β transforming growth factor beta induces epithelial-mesenchymal transition in colon cancer cell lines with the microsatellite stability, inducing cell invasion and migration.

EMT is a critical early event involved in invasion and metastasis of colorectal cancer, characterized by the presence of markers specific to each phenotype, epithelial or mesenchymal. Multiple biomarkers involved in the induction of EMT may represent future therapeutic target in the treatment of colonic neoplasia.

Glimelius B, Oliveira J.